Table 3.

Patient follow up during the last year of life.

	N=100
Localization at death  Home  Local hospital  Geriatrics  Palliative care  Hematology/specialized department  ICU	20 8 12 20 25 15
Time between last treatment and death (days)	38 (1-2443)
Number of imagery exams during last year	7 (0-25)
Treatment received during last year Steroids and palliative Anticoagulants/antiagregants Antiinfectious (preventive) Biphosphonates Growth factors RBC transfusions Platelet transfusions IMIDs Proteasome inhibitors Melphalan High dose Mel with ASCT Anti CD38 Clinical trial Anti-infectious (curative) Painkillers	92 68 74 31 44 52 31 71 54 2 1 44 5 49 66
Response to last therapy CR/VGPR PR SD PD Non evaluable	5 7 8 75 5
Disease status at death  Remission/stable  Progressive  Unknown	18 77 5
Biology at time of death  Hypercalcemia > 2.5 mM  Anemia (Hb<90g/L)  Renal failure (creat >110)  Neutropenia  Lymphopenia < 1 giga/L  Thrombocytopenia < 50 giga/L	24 52 49 17 73 40
Immediate cause of death£  Myeloma progression  Other disease, including:   Other neoplasia   Neurological diseases  Infection  DVT  Treatment related toxicity	78 23 7 4 36 (including 4 Covid) 3 32

CR, complete response; DVT, deep vein thrombosis; PR, partial response; SD, stable disease; VGPR, very good partial response; ICU, intensive care unit; RBC, red blood cell; IMID, immunomodulatory drugs; Mel, Melphalan. £: the total value of causes exceeds 100 as several causes were deemed involved in occurrence of death in certain patients.